Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Mania and Antimanic Drugs: Overview01:24

Mania and Antimanic Drugs: Overview

302
Mania, a psychological condition characterized by elevated mood, increased energy, and reduced sleep need, is part of the bipolar disorder cycle. The exact cause of mania isn't entirely known, but it is thought to be a combination of genetic, environmental, and neurological factors. Bipolar disorder involves alternating manic and depressive episodes. Mood stabilizers like lithium, antipsychotics, and anticonvulsants help manage these episodes. Lithium carbonate is particularly effective as...
302
Bipolar Disorder01:30

Bipolar Disorder

124
Bipolar disorder is a chronic mental health condition marked by significant mood fluctuations, including episodes of mania and depression. Elevated energy levels, heightened mood or irritability, impulsive behavior, reduced sleep needs, rapid speech, racing thoughts, inflated self-esteem, and distractibility characterize mania. Individuals with bipolar disorder often alternate between depressive and manic states, with periods of emotional stability lasting an average of six months to a year.
124
Drug Therapy01:28

Drug Therapy

89
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
89
Diagnostic and Statistical Manual of Mental Disorders (DSM)01:27

Diagnostic and Statistical Manual of Mental Disorders (DSM)

118
The Diagnostic and Statistical Manual of Mental Disorders (DSM) serves as the primary classification system for mental health disorders, providing standardized diagnostic criteria for clinicians and researchers. First published by the American Psychiatric Association (APA) in 1952, the DSM has undergone several revisions to reflect evolving psychiatric understanding. The fifth edition, DSM-5, released in 2013, introduced key updates that expanded diagnostic categories and modified diagnostic...
118
Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

308
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
308
Antidepressant Drugs: Overview01:25

Antidepressant Drugs: Overview

693
Antidepressant drugs are a class of medications primarily used for treating various mood disorders, including major depression, anxiety disorders, and other related conditions. These medicines work by modulating the neurotransmitter balance within the brain, alleviating depressive symptoms. Antidepressants can be broadly categorized into several groups according to their mechanism of action and chemical structure: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine...
693

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Organizational Stressors, Burnout, and Mental Health Outcomes Among Local Government Employees During Disaster Response.

Journal of occupational and environmental medicine·2026
Same author

Effect of Social Support on Suicide Risk among Posttraumatic Stress Disorder, Depressive, and Comorbid Symptom Groups in Elderly Living Alone in Korea.

Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology·2026
Same author

Comparative efficacy and safety of liraglutide versus metformin, naltrexone/bupropion, and phentermine-topiramate in psychiatric patients.

Therapeutic advances in psychopharmacology·2026
Same author

Deep neural network-based analysis of voice biomarkers for monitoring treatment response in adolescent major depressive disorder.

Communications medicine·2026
Same author

Korean Medication Algorithm Project for Depressive Disorder 2025: Comparisons with Other Treatment Guidelines.

Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology·2026
Same author

Brexpiprazole for the Treatment of Agitation Associated with Dementia due to Alzheimer's Disease: Clinical Perspectives.

Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology·2026
Same journal

Psychosis in a 47,XXX Adolescent: Clinical Management and Multidisciplinary Follow-up.

Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology·2026
Same journal

Guanfacine as a Treatment Option for Persistent Mental Restlessness and Deliberate Self-harm Thoughts in a Patient with Attention-deficit/Hyperactivity Disorder, Autism Spectrum Disorder, Borderline Personality Disorder, and Post-traumatic Stress Disorder: Case Report.

Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology·2026
Same journal

Delirious Mania with Mild Encephalitis and a Reversible Splenial Lesion Successfully Treated with Electroconvulsive Therapy: A Case Report.

Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology·2026
Same journal

Time-limited Moderating Effect of Neuroticism on the Cortisol-Depression Relationship after Physical Injury.

Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology·2026
Same journal

Antibiotic-induced Microbiome Depletion Selectively Reduces Baseline Hypothalamic Oxytocin Signaling without Affecting MDMA-induced Oxytocin Response in Rats.

Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology·2026
Same journal

Early Individualized Psychological Intervention Using Virtual Reality-assisted Decision System Reduces Decisional Conflict in Patients with Pulmonary Nodules: A Randomized Controlled Trial.

Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology·2026
See all related articles

Related Experiment Video

Updated: Aug 24, 2025

Developing a Rat Model for Bipolar Disorder
04:44

Developing a Rat Model for Bipolar Disorder

Published on: May 2, 2025

428

Korean Medication Algorithm Project for Bipolar Disorder 2022, Fifth Revision: An Executive Summary.

Young Sup Woo1, Won-Myong Bahk1, Jong-Hyun Jeong1

  • 1Department of Psychiatry, College of Medicine, The Catholic University of Korea, Seoul, Korea.

Clinical Psychopharmacology and Neuroscience : the Official Scientific Journal of the Korean College of Neuropsychopharmacology
|October 20, 2022
PubMed
Summary
This summary is machine-generated.

The revised Korean Medication Algorithm Project for Bipolar Disorder (KMAP-BP) offers updated treatment guidelines for bipolar disorder. New recommendations focus on pharmacotherapy for manic, depressive, and mixed episodes in adults and youth.

Keywords:
Bipolar disorderExpert consensusKMAP-BP 2022Pharmacotherapy

More Related Videos

Implementation of a Real-Time Psychosis Risk Detection and Alerting System Based on Electronic Health Records using CogStack
07:31

Implementation of a Real-Time Psychosis Risk Detection and Alerting System Based on Electronic Health Records using CogStack

Published on: May 15, 2020

7.2K
Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression
04:29

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression

Published on: January 7, 2019

28.8K

Related Experiment Videos

Last Updated: Aug 24, 2025

Developing a Rat Model for Bipolar Disorder
04:44

Developing a Rat Model for Bipolar Disorder

Published on: May 2, 2025

428
Implementation of a Real-Time Psychosis Risk Detection and Alerting System Based on Electronic Health Records using CogStack
07:31

Implementation of a Real-Time Psychosis Risk Detection and Alerting System Based on Electronic Health Records using CogStack

Published on: May 15, 2020

7.2K
Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression
04:29

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression

Published on: January 7, 2019

28.8K

Area of Science:

  • Psychiatry
  • Pharmacology
  • Clinical Medicine

Background:

  • The Korean Medication Algorithm Project for Bipolar Disorder (KMAP-BP) has been periodically updated since 2002.
  • The latest revision, KMAP-BP 2022, incorporates recent advancements in bipolar disorder treatment.

Purpose of the Study:

  • To revise the KMAP-BP guidelines based on current scientific evidence and clinical consensus.
  • To provide updated pharmacotherapy recommendations for various phases of bipolar disorder.

Main Methods:

  • A consensus-based approach involving 87 Korean psychiatrists and 40 child and adolescent psychiatry experts.
  • Questionnaires with 56 items for adults and 7 items for pediatric patients were utilized.

Main Results:

  • First-line treatments for manic episodes include mood stabilizer (MS) or atypical antipsychotic (AAP) monotherapy, or a combination of MS and AAP.
  • For depressive episodes, first-line options include combinations of MS and AAP, or AAP and lamotrigine (LMT), or monotherapy with MS, AAP, or LMT.
  • Treatment for mixed features recommends MS and AAP combination or monotherapy, with AAP and LMT or MS and LMT as options for depressive mixed states.

Conclusions:

  • The KMAP-BP 2022 reflects changes in Korean healthcare and society, alongside new pharmacotherapy evidence.
  • These updated guidelines offer valuable information for clinicians managing bipolar disorder patients.